Express Scripts will add approved lower-cost generics to its National Preferred Flex Formulary and exclude the branded drug, and possibly other drugs in the therapy class, from its coverage.
The ad is aimed at President Donald Trump and a specific proposal known as "patient definition" that has been floated in the administration's drug pricing blueprint.
The FDA on Nov. 2 approved a new super-potent opioid tablet for use in hospitals. While prescribing numbers for opioids have been declining for the past few years, prescription use of painkillers still present a major challenge for combating the overall opioid crisis.
Providers can breathe a sigh of relief as a split House and Senate likely means that most of the sweeping healthcare policy changes are off the table until 2020. Plus, they may join forces with lawmakers on a common enemy: pharma.
Surgeons write opioid prescriptions for four times as many pills as patients actually use, according to a study that found that prescription quantity, not reported pain, is the strongest predictor of opioid consumption.
Alabama's largest health insurer will stop covering OxyContin prescriptions as part of an effort to deter opioid abuse.
The Wixom, Mich.-based bioscience technology company appointed Angus Smith to oversee financial operations effective later this month, according to a Friday announcement from the company.
The Food and Drug Administration approved a fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals. The decision came over objections that the pill could be abused.
John Hammergren is retiring after more than 17 years at the helm of the drug distributor. The company's current COO will take over as CEO, and the current lead independent director will take over as chairman.
The former CVS Caremark executive was brought into HHS to lead the drive to lower drug prices.
HHS will reverse course and allow a ceiling price rule for the 340B program to kick in Jan.1, 2019 instead of the previously set July 1 launch date. The limits have been delayed five times over the years.
The Trump administration's latest step to tackle high drug prices has generated praise, criticism and a lot of questions from providers, payers and drugmakers. Modern Healthcare runs down five of the top questions.